Lawrence Schachner, MD, discusses recent developments in the pediatric atopic dermatitis treatment landscape, including:

  • Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?
  • Dupilumab is currently approved for patients with atopic dermatitis aged 6 years and older. Do you foresee dupilumab being approved for even younger patients in the near future?
  • How do emerging JAK inhibitors fit into the existing treatment landscape for pediatric patients with atopic dermatitis?

See All 78 Episodes of "DermDocs"